NCT00369512View on ClinicalTrials.gov

A Trial of Erlotinib + Radiotherapy for Cutaneous Squamous Cell Carcinoma

PHASE2CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

August 31, 2006

Primary Completion Date

January 31, 2012

Study Completion Date

September 30, 2012

Conditions
Cancer
Interventions
DRUG

Erlotinib

Erlotinib therapy for 2 weeks (150 mg po qd)(for those who are enrolled before surgery is done), surgery/biopsy up to 8 weeks recovery, radiation/Erlotinib therapy for 6 weeks (150mg po qd).

Trial Locations (1)

35233

University of Alabama at Birmingham Medical Center, Birmingham

Sponsors
All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

collaborator

OSI Pharmaceuticals

INDUSTRY

lead

University of Alabama at Birmingham

OTHER